Testing for gene mutations responsible for resistance to endocrine or CDK4/6 (cyclin-dependent kinase 4/6) inhibitor therapy either from tumour tissue or free circulating tumour DNA isolated from plasma are another group of multigene tests. The gene discussed is CDK4; the disease is neoplasm.